The 10th meeting of the Federation of Clinical Immunology Societies (FOCIS) was held in Boston during 23-27 June 2010. As usual, this conference highlights the greatest advancements in the field of clinical immunology over the previous year. It is especially remarkable since this is the 10th meeting and many programs were set up to celebrate this decade of FOCIS meetings. Two of the FOCIS founders, Drs Garrison Fathman and David Hafler, made special lectures in FOCIS Founder Symposium and both speakers emphasized that FOCIS provides a platform for clinicians and scientists to meet to discuss the commonalities of immunebased diseases. They expressed their belief that advances in immune-based pathophysiology can be encompassed by the five pillars of FOCIS: immunoregulation, immunogenetic/genomics, immunotherapy, immunodiagnosis/immune monitoring and host defense. More than 450 participants attended the meeting, which comprised 4 keynote addresses, 60 plenary lectures and 94 selected oral presentations. In addition, 344 posters were presented to an interested audience.
The development of regulatory T cell therapy seems to be one of quickest steps moving forward to clinical trial in autoimmune diseases, organ transplantation allograft protection and the prevention of severe side effect of acute graft-versus-host disease (GVHD) in stem cell transplantation.
Bruce Blazar at University of Minnesota reported the safety of his natural Treg cells (nTregs) ex vivo expanded from umbilical cord blood (UCB) in patients with hematopoietic malignancies who had received bone morrow stem cell therapy. His data revealed that the side effects of nTreg cell expanded from complete and partial MHC-matched UCB were minor when nTreg cell product was used with the dose up to 3 × 10 6 cells/kg. This group also observed that injection of nTreg cells could significantly decrease the incidence of I-II GVHD to 39% (n ¼ 18) versus control groups (61%, n ¼ 115) in patients who received bone morrow stem cell therapy. However, it is noted that there were 39% of patients who received stem cells and nTreg cell therapy will still develop GVHD, suggesting that improvement for this nTreg therapy protocol is desirable. Previous studies have revealed that adoptive transfer of nTreg cells was able to prevent but unable to treat the established autoimmune diseases such as collagen-induced arthritis (Bardos et al., 2003; Morgan et al., 2005) . Song Guo Zheng's group at University of Southern California has discovered that addition of all-trans-retinoic acid (atRA) now can overcome the plasticity and restore the functionality of nTreg cells in the inflammatory milieu. More importantly, this group has also found that nTreg cells pre-treated with atRA were completely resistant to Th17 cell conversion when stimulated with IL-6, and restored the suppressive effects in vitro in the presence of IL-6 and on established autoimmune arthritis in vivo. These data implicate that atRA-treated nTreg cells may have an important therapeutic role in the treatment of patients with autoimmune diseases.
It is still unclear whether increased responder T cell resistance or impaired Treg cell suppressive activity mainly contribute to the pathogenesis and development of autoimmune diseases. (Annunziato et al., 2009; Louten et al., 2009; Pernis, 2009) . In some cases, the combination of Th1 and Th17 cells is necessary for the disease development. Rachel Caspi's group at the NIH reported an interesting finding where they demonstrated that even a combined defect of Th1 and Th17 cells did not affect the development of ocular autoimmunity. They further found that IL-17F is elevated in IFN-and IL-17A double KO mice. 
